检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.

Alejo Rodriguez-Vida,Pablo Maroto,Albert Font,Cristina Martin,Begoña Mellado,Alex Corbera,Mayra Orrillo,Oscar Reig,Rosa Querol,Alejandro Rios-Hoyo,Laia Cano,Judith Alonso,Gemma Martinez, Susana Galtes,Alvaro Taus,Maria Martinez-Garcia,Nuria Juanpere,Oscar Juan,Joaquim Bellmunt

British journal of cancer（2023）

引用 1|浏览27
暂无评分
摘要
Avelumab plus carboplatin has an acceptable safety profile and was associated with a prolonged OS given the heavily pretreated population.
更多
查看译文
关键词
Cancer immunotherapy,Prostate cancer,Biomedicine,general,Cancer Research,Epidemiology,Molecular Medicine,Oncology,Drug Resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要